PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsRurioctocog alfa pegol
Antihemophilic factor pegylated (mw 20000) human sequence recombinant
Antihemophilic factor, pegylated (mw 20000) human sequence recombinant is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
394 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hemophilia aD006467EFO_0007267D66463811352118343
Blood coagulation disordersD001778EFO_0009314D68.9411231029
Hemophilia bD002836—D67221221128
Hemostatic disordersD020141——4283622
Von willebrand diseasesD014842EFO_0003910D68.012143221
HemorrhageD006470MP_0001914R58——43613
Hematologic diseasesD006402EFO_0005803D75.91132410
Coagulation protein disordersD020147————4138
Inherited blood coagulation disordersD025861————2136
RecurrenceD012008—————123
Show 6 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hemorrhagic disordersD006474—D69.9——3—25
Inborn genetic diseasesD030342EFO_0000508———2—24
Type 3 von willebrand diseaseD056729Orphanet_166096D68.031—1—24
X-linked genetic diseasesD040181————1—12
Bone diseasesD001847—M89.9——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———41———5
Genetic therapyD015316——11——12
Systemic sclerodermaD012595EFO_0000717M34—1———1
Raynaud diseaseD011928EFO_1001145I73.0—1———1
Brain neoplasmsD001932EFO_0003833C71—1———1
GlioblastomaD005909EFO_0000515——1———1
HemostasisD006487———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiovascular diseasesD002318EFO_0000319I981————1
MenorrhagiaD008595EFO_0003945N92.01————1
Factor vii deficiencyD005168—D68.21————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G35————33
SclerosisD012598——————33
Motor activityD009043EFO_0003940—————22
ThrombosisD013927——————22
InfertilityD007246EFO_0000545—————22
Breast neoplasmsD001943EFO_0003869C50————11
SeromaD049291——————11
Relapsing-remitting multiple sclerosisD020529EFO_0003929—————11
Replacement arthroplastyD019643——————11
Sickle cell anemiaD000755EFO_0000697D57————11
Show 38 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAntihemophilic factor pegylated (mw 20000) human sequence recombinant
INNrurioctocog alfa pegol
Description
Antihemophilic factor, pegylated (mw 20000) human sequence recombinant is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Classification
Unknown
Drug classPEGylated compounds, covalent attachment of macrogol (polyethylene glycol) polymer
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL4594584
ChEBI ID—
PubChem CID—
DrugBank—
UNII ID5X3GF74R79 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
717 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use